| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $196,731 | 4 | 100 |
Sells | $0 | 0 | 0 |
| Hitchcock Michael J.M. | Interim CEO | 1 | $99,180 | 0 | $0 | $99,180 |
| Erdtmann Rainer M | See Remarks | 3 | $97,551 | 0 | $0 | $97,551 |
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Over the last 12 months, insiders at Biomea Fusion, Inc. have bought $196,731 and sold $0 worth of Biomea Fusion, Inc. stock.
On average, over the past 5 years, insiders at Biomea Fusion, Inc. have bought $3.73M and sold $13.28M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hitchcock Michael J.M. (Interim CEO) — $99,180. Erdtmann Rainer M (See Remarks) — $97,551.
The last purchase of 30,000 shares for transaction amount of $42,999 was made by Erdtmann Rainer M (See Remarks) on 2025‑12‑11.
| 2025-12-11 | Erdtmann Rainer M | See Remarks | 30,000 0.0475% | $1.43 | $42,999 | -11.84% | ||
| 2025-12-02 | Hitchcock Michael J.M. | Interim CEO | 100,000 0.1741% | $0.99 | $99,180 | +39.98% | ||
| 2025-12-01 | Erdtmann Rainer M | See Remarks | 10,000 0.0175% | $1.05 | $10,500 | +32.67% | ||
| 2025-11-28 | Erdtmann Rainer M | See Remarks | 40,000 0.0682% | $1.10 | $44,052 | +22.94% | ||
| 2024-09-30 | Hitchcock Michael J.M. | director | 10,000 0.029% | $10.06 | $100,600 | -75.20% | ||
| 2024-06-11 | Valle Franco | Chief Financial Officer | 12,509 0.0348% | $4.43 | $55,361 | +1.92% | ||
| 2023-06-01 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 50,000 0.1638% | $34.56 | $1.73M | -57.49% | |
| 2023-05-31 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 75,000 0.2524% | $33.81 | $2.54M | -55.29% | |
| 2023-05-12 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 25,000 0.0841% | $33.84 | $846,000 | -53.59% | |
| 2023-05-09 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 150,000 0.5185% | $34.50 | $5.18M | -53.05% | |
| 2023-05-08 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 100,000 0.3445% | $33.99 | $3.4M | -52.35% | |
| 2023-04-20 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 200,000 0.6723% | $29.12 | $5.82M | -43.68% | |
| 2023-03-31 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 200,000 0.6812% | $31.25 | $6.25M | -45.45% | |
| 2023-03-30 | Chen Bihua | 400,000 1.2695% | $30.00 | $12M | -47.02% | |||
| 2022-11-14 | Hitchcock Michael J.M. | director | 5,000 0.0169% | $7.93 | $39,650 | +88.58% | ||
| 2022-11-11 | Valle Franco | Chief Financial Officer | 4,100 0.0134% | $7.63 | $31,286 | +90.83% | ||
| 2022-08-16 | A2A Pharmaceuticals, Inc. | 30,684 0.1067% | $13.87 | $425,648 | -9.55% | |||
| 2022-07-21 | Sale | A2A Pharmaceuticals, Inc. | 34,658 0.1118% | $11.21 | $388,516 | -2.11% | ||
| 2022-06-24 | Sale | A2A Pharmaceuticals, Inc. | 34,658 0.1168% | $11.76 | $407,578 | -5.69% | ||
| 2022-01-14 | Valle Franco | Chief Financial Officer | 10,000 0.033% | $8.68 | $86,767 | -17.39% |
| Erdtmann Rainer M | See Remarks | 723027 1.2152% | $1.6M | 7 | 0 | <0.0001% |
| Hitchcock Michael J.M. | Interim CEO | 115000 0.1933% | $254,150.00 | 3 | 0 | +6.69% |
| Stergiopoulos Sotirios | director | 4400000 7.3954% | $9.72M | 1 | 0 | <0.0001% |
| Chen Bihua | 3570872 6.0018% | $7.89M | 2 | 0 | <0.0001% | |
| A2A Pharmaceuticals, Inc. | 10 percent owner | 3500000 5.8827% | $7.74M | 2 | 9 | <0.0001% |
| Butler Thomas Andrew | CEO | 228470 0.384% | $504,918.70 | 4 | 0 | <0.0001% |
| Valle Franco | Chief Financial Officer | 42500 0.0714% | $93,925.00 | 3 | 0 | +25.12% |
$9,405,928 | 107 | 12.61% | $132.75M | |
$22,693,451 | 105 | 8.15% | $161.28M | |
$87,639,490 | 62 | 18.37% | $108.33M | |
$18,994,888 | 46 | 88.59% | $123.06M | |
$48,218,096 | 42 | 0.89% | $108.54M | |
$7,147,964 | 34 | 24.77% | $156.93M | |
$109,415,500 | 33 | 18.13% | $157.94M | |
$47,292,212 | 27 | -28.21% | $111.34M | |
$295,092,700 | 21 | -0.27% | $161.61M | |
$161,692,548 | 20 | 18.00% | $130.3M | |
Biomea Fusion, Inc. (BMEA) | $33,128,160 | 18 | -13.64% | $131.49M |
$9,999,920 | 10 | -40.03% | $135.27M | |
$2,762,881 | 8 | -10.76% | $129.94M | |
$43,340,011 | 7 | 45.36% | $117.5M | |
$22,090,972 | 7 | -3.49% | $159.2M | |
$68,692,148 | 6 | -39.10% | $112.84M | |
$112,382,168 | 4 | -48.89% | $113.71M | |
$12,750 | 2 | -39.73% | $162.97M | |
$19,848 | 2 | -11.42% | $135.98M |
| Increased Positions | 26 | +27.66% | 5M | +19.42% |
| Decreased Positions | 38 | -40.43% | 7M | -26.71% |
| New Positions | 8 | New | 959,983 | New |
| Sold Out Positions | 20 | Sold Out | 5M | Sold Out |
| Total Postitions | 82 | -12.77% | 23M | -7.29% |
| Fmr Llc | $10,207.00 | 10.73% | 7.62M | +372,940 | +5.15% | 2025-09-30 |
| Cormorant Asset Management, Lp | $4,785.00 | 5.03% | 3.57M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $2,908.00 | 3.06% | 2.17M | +290,376 | +15.45% | 2025-09-30 |
| Aisling Capital Management Lp | $2,745.00 | 2.89% | 2.05M | 0 | 0% | 2025-09-30 |
| Heights Capital Management, Inc | $1,926.00 | 2.03% | 1.44M | -2M | -62.55% | 2025-09-30 |
| Woodline Partners Lp | $1,743.00 | 1.83% | 1.3M | -443,000 | -25.4% | 2025-09-30 |
| Blackrock, Inc. | $1,208.00 | 1.27% | 901,555 | +148,004 | +19.64% | 2025-09-30 |
| Renaissance Technologies Llc | $799.00 | 0.84% | 595,900 | +595,900 | New | 2025-09-30 |
| Federated Hermes, Inc. | $767.00 | 0.81% | 572,043 | -4,321 | -0.75% | 2025-09-30 |
| Two Sigma Investments, Lp | $754.00 | 0.79% | 562,968 | +213,321 | +61.01% | 2025-09-30 |